LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Search

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

2.47 -2.76

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.4699999999999998

Максимум

2.58

Ключови измерители

By Trading Economics

Приходи

4.1M

-5.7M

Служители

34

EBITDA

3.1M

-6.8M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+687.4% upside

Дивиденти

By Dow Jones

Следващи печалби

16.06.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-146M

243M

Предишно отваряне

5.23

Предишно затваряне

2.47

Настроения в новините

By Acuity

50%

50%

154 / 344 Класиране в Healthcare

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.06.2026 г., 23:36 ч. UTC

Печалби

Correction to Oracle Reports Higher 4Q Profit Article

10.06.2026 г., 23:19 ч. UTC

Горещи акции

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10.06.2026 г., 23:09 ч. UTC

Значими двигатели на пазара

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10.06.2026 г., 23:04 ч. UTC

Печалби

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10.06.2026 г., 20:44 ч. UTC

Значими двигатели на пазара

Caterpillar Raises Quarterly Dividend 8%

10.06.2026 г., 23:49 ч. UTC

Придобивния, сливания и поглъщания

Elliott: Northern Star Should Take No Options Off The Table

10.06.2026 г., 23:48 ч. UTC

Придобивния, сливания и поглъщания

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10.06.2026 г., 23:48 ч. UTC

Придобивния, сливания и поглъщания

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10.06.2026 г., 23:47 ч. UTC

Пазарно говорене

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10.06.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10.06.2026 г., 23:46 ч. UTC

Придобивния, сливания и поглъщания

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10.06.2026 г., 23:38 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

10.06.2026 г., 23:38 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

10.06.2026 г., 23:38 ч. UTC

Пазарно говорене

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10.06.2026 г., 23:32 ч. UTC

Пазарно говорене

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10.06.2026 г., 23:20 ч. UTC

Пазарно говорене

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10.06.2026 г., 22:05 ч. UTC

Пазарно говорене

Correction to Bank of Canada Stays on Hold Market Talk

10.06.2026 г., 21:57 ч. UTC

Печалби

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10.06.2026 г., 21:52 ч. UTC

Печалби

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10.06.2026 г., 21:35 ч. UTC

Печалби

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10.06.2026 г., 21:22 ч. UTC

Печалби

Oracle Stock Slides on Increased Capital Spending -- WSJ

10.06.2026 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

10.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

10.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

10.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.06.2026 г., 20:39 ч. UTC

Пазарно говорене
Печалби

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10.06.2026 г., 20:34 ч. UTC

Печалби

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10.06.2026 г., 20:33 ч. UTC

Печалби

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10.06.2026 г., 20:33 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

10.06.2026 г., 20:33 ч. UTC

Пазарно говорене
Печалби

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

687.4% нагоре

12-месечна прогноза

Среден 20 USD  687.4%

Висок 20 USD

Нисък 20 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Настроение

By Acuity

154 / 344 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
help-icon Live chat